ArticleCell metabolism2008
T cells potentiate PTH-induced cortical bone loss through CD40L signaling.
Article in Cell metabolism, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 133 citations in OpenAlex.
- Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013Trial
- The importance of B cells for osteogenic homeostasis.Cell communication and signaling : CCS · 2026Article
- Bacterial specificity of the gut microbiome predicts bone density in primary hyperparathyroidism.Bone research · 2026Article
- Immunoporosis: The hidden link between aging immune cells and bone fragility.Journal of orthopaedic translation · 2025Review
- Review
- Hydroxyurea blunts mitochondrial energy metabolism and osteoblast and osteoclast differentiation exacerbating trabecular bone loss in sickle cell mice.Cell death & disease · 2024Article
- Patients with ankylosing spondylitis present a distinct CD8 T cell subset with osteogenic and cytotoxic potential.RMD open · 2024Article
- Inflammation and gut dysbiosis as drivers of CKD-MBD.Nature reviews. Nephrology · 2023Review
- TRAF-STOP alleviates osteoclastogenesis in periodontitis.Frontiers in pharmacology · 2023Article
- The associations of gut microbiota, endocrine system and bone metabolism.Frontiers in microbiology · 2023Review
- The osteocyte as a signaling cell.Physiological reviews · 2022Review
- Beyond Bone: Infectious Diseases and Immunity in Parathyroid Disorders.Advances in experimental medicine and biology · 2022Article
- The immune factors have complex causal regulation effects on bone mineral density.Frontiers in immunology · 2022Article
- Systems pharmacology dissection of action mechanisms for herbs in osteoporosis treatment.Chinese herbal medicines · 2021Article
- Targeting Histone Modifications in Bone and Lung Metastatic Cancers.Current osteoporosis reports · 2021Review
- Role of Gut Microbiota in the Skeletal Response to PTH.The Journal of clinical endocrinology and metabolism · 2021Review
- The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders.Frontiers in endocrinology · 2021Review
- PTH induces bone loss via microbial-dependent expansion of intestinal TNFNature communications · 2020Article
- A Comprehensive Analysis of MicroRNAs in Human Osteoporosis.Frontiers in endocrinology · 2020Article
- Osteoporosis: Pathophysiology and therapeutic options.EXCLI journal · 2020Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Parathyroid hormone (PTH) promotes bone catabolism by targeting bone marrow (BM) stromal cells (SCs) and their osteoblastic progeny. Here we show that a continuous infusion of PTH that mimics hyperparathyroidism fails to induce osteoclast formation, bone resorption, and cortical bone loss in mice lacking T cells. T cells provide proliferative and survival cues to SCs and sensitize SCs to PTH through CD40 ligand (CD40L), a surface molecule of activated T cells that induces CD40 signaling in SCs. As a result, deletion of T cells or T cell-expressed CD40L blunts the bone catabolic activity of PTH by decreasing bone marrow SC number, the receptor activator of nuclear factor-kappaB ligand (RANKL)/OSTEOPROTEGERN (OPG) ratio, and osteoclastogenic activity. Therefore, T cells play an essential permissive role in hyperparathyroidism as they influence SC proliferation, life span, and function through CD40L. T cell-SC crosstalk pathways may thus provide pharmacological targets for PTH-induced bone disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.